復星醫藥(600196.SH):子公司江蘇萬邦擬終止萬格列淨片的臨牀試驗及後續開發
格隆匯12月28日丨復星醫藥(600196.SH)公佈,公司控股子公司江蘇萬邦生化醫藥集團有限責任公司(“江蘇萬邦”)萬格列淨片於中國境內(不包括港澳台,下同)處於I期臨牀試驗階段。近日,經審慎考量,基於對該新藥後續開發投入和市場價值等因素的綜合評估,為合理配置研發資源、聚焦研發管線中的優勢項目,江蘇萬邦決定終止該新藥的臨牀試驗及後續開發。
該新藥為SGLT-2抑制劑,擬主要用於II型糖尿病的治療。根據IQVIA CHPA最新數據,2020年度,SGLT-2抑制劑於中國境內銷售額約為人民幣9.66億元。
由於該新藥目前尚處於I期臨牀試驗階段,而國內外均已有多款SGLT-2抑制劑上市、市場競爭已相對激烈,經審慎考量,基於對該新藥後續開發投入和市場價值等因素的綜合評估,為合理配置研發資源、聚焦研發管線中的優勢項目,江蘇萬邦決定終止該新藥的臨牀試驗及後續開發。
截至公吿日,集團(公司及控股子公司/單位,下同)現階段針對該新藥累計全部研發投入約為人民幣5523萬元(未經審計;包含許可費)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.